Evidence map›Paper›PMID 30740317›Full record

ArticleCardiovascular diagnosis and therapy2018

The transition of pediatric Marfan patients to adult care: a challenge and its risks.

Veronika C Stark, Katrin Doering, Yskert von Kodolitsch, Rainer Kozlik-Feldmann, Götz C Mueller, Jakob Olfe, Meike Rybczynski, Helke Schueler, Thomas S Mir

Abstract read
In one paragraph

Article in Cardiovascular diagnosis and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Marfan syndrome.Nature reviews. Disease primers · 2021
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Veronika C StarkPediatric Cardiology, University Heart Center, Hamburg, Germany.
Katrin DoeringPediatric Cardiology, University Heart Center, Hamburg, Germany.
Yskert von KodolitschCardiology, University Heart Center, Hamburg, Germany.
Rainer Kozlik-FeldmannPediatric Cardiology, University Heart Center, Hamburg, Germany.
Götz C MuellerPediatric Cardiology, University Heart Center, Hamburg, Germany.
Jakob OlfePediatric Cardiology, University Heart Center, Hamburg, Germany.
Meike RybczynskiCardiology, University Heart Center, Hamburg, Germany.
Helke SchuelerCardiology, University Heart Center, Hamburg, Germany.
Thomas S MirPediatric Cardiology, University Heart Center, Hamburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCare for patients with Marfan syndrome (MFS) has improved substantially in recent decades. Increasing clinical knowledge and genetic analysis allow early diagnosis of the disease in childhood. Because of the earlier initiation to preventive and medical treatment, patients' life expectancy has risen. To ensure optimal care, pediatric patients require a safe follow-up regime, multidisciplinary care, and a safe transition to adult care.

methodsWe collected a sample of 149 pediatric Marfan patients, of whom 34 patients had already been transferred to adult care or who were currently transitioning. First, we evaluated clinical aspects of patients that manifest in childhood and are present in the transition process. Second, we analyzed the transition process itself.

resultsWe found age-dependent manifestation of organ pathologies. Dilatation of the sinus of Valsalva showed a particularly high prevalence during the transition process and 62% of patients required medical treatment. Mean onset of aortic root dilatation was 9.9±5.8 years. Concerning systemic manifestation in MFS skin striae, wrist and thumb sign, and reduced elbow extension occurred significantly more often in patients who were transitioning than in younger children with MFS. All other clinical Marfan features showed an increased prevalence in patients who were transitioning compared with younger patients. In our cohort, transition was successful in 20 patients (58.9%), 12 patients (35.3%) are still in the transition process and 2 patients (5.9%) were lost to follow up.

conclusionsMarfan patients in the transition process are already under a chronic disease condition with a high onset of especially cardiovascular pathologies. Although early medical treatment in childhood is effective, the pathologies of the connective tissue require lifelong attention and influence life in many ways. The big challenge during transition is the double change of responsibility from the parents and pediatric doctor to the patient and adult doctor. Consequently, patients in transition process require special attention and close contact with the doctor and the family. A reevaluation by the supervising pediatric Marfan specialist of the successful transition to adult care is indispensable before the pediatric care of Marfan patients is completed.

Indexed as

Aortic dilatationMarfan syndrome (MFS)medical treatmentsystemic manifestationtransition process

Identifiers

PMID30740317
PMCPMC6331371

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.